Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05078775 · ClinicalTrials.gov registry record · NA
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
A NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by Faeth Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 9
- Study locations
NCT05078775: Completed NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by Faeth Therapeutics.
NCT05078775 is a NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma that has completed, run by Faeth Therapeutics. The registered enrollment target is 39 participants, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (56% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05078775, a NA study of Metastatic Pancreatic Adenocarcinoma and Locally Advanced Unresectable Pancreatic Adenocarcinoma, has completed, sponsored by Faeth Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.
Primary Outcome
The primary endpoint is the rate of the most common Grade 3 and 4 adverse event (AE) related to the NEAAR medical food.
Conditions Studied
Interventions
- OTHER NEAAR Medical Food
Study Locations (9)
California
- Oncology Physicians Network - Glendale
- Cedars-Sinai - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
Arizona
- University of Arizona Cancer Center - Tucson
Florida
- Florida Cancer Specialists - Fort Myers
New Jersey
- Atlantic Health - Morristown
North Carolina
- xCures - Virtual Site - Raleigh
Tennessee
- Sarah Cannon - Nashville
Texas
- Baptist Hospitals of Southeast Texas - Beaumont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2025-07-10 |
| Phase | NA |
What the finished NCT05078775 record still lists
NCT05078775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 89-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which NEAAR Medical Food is the first listed.
NCT05078775 lists 9 locations in 7 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT05078775 about?
NCT05078775 is a clinical study titled "Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer". This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are el...
What is the current status of trial NCT05078775?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2021-12-21. Estimated completion is 2025-07-10.
What conditions does trial NCT05078775 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05078775?
The interventions under investigation include: NEAAR Medical Food (OTHER).
Who is sponsoring clinical trial NCT05078775?
This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05078775 being conducted?
This trial has 9 study locations across Arizona, California, Florida, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05078775's enrollment target sits among peer trials
39 23rd of 37 higher than 14 of 37 other Metastatic Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
RECRUITING · NA
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
RECRUITING · Phase 3
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI